# Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Source: https://onco.cc/trials/nct05911295/  
OnCo record `nct05911295` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Disitamab vedotin, Pembrolizumab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.

## Summary

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 is a phase 3 interventional study registered as NCT05911295 by Seagen, a wholly owned subsidiary of Pfizer, with 412 participants enrolled, started 2023-09-22 and due to reach its primary completion in 2027-01-29. Interventions recorded: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin and carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05911295
- Phase: 3
- Setting: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Enrolled: 412

## Sources

- ClinicalTrials.gov NCT05911295: https://clinicaltrials.gov/study/NCT05911295

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct05911295.json